Sanofi: new positive results for Dupixent
(CercleFinance.com) - Sanofi today announces new positive results for a Phase 3 open-label extension trial for Dupixent in adults and adolescents with moderate-to-severe asthma, which will be presented at the International Congress of the European Pneumological Society.
The data showed that the safety and efficacy profiles observed in previous trials of this drug have been maintained for up to three years, the health group said.
The results of the analyses concern include more than 2,200 patients who previously participated in Dupixent asthma trials, including three pivotal trials that lasted between 24 and 52 weeks.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The data showed that the safety and efficacy profiles observed in previous trials of this drug have been maintained for up to three years, the health group said.
The results of the analyses concern include more than 2,200 patients who previously participated in Dupixent asthma trials, including three pivotal trials that lasted between 24 and 52 weeks.
Copyright (c) 2020 CercleFinance.com. All rights reserved.